|
Delayed
Nasdaq Stockholm
05:19:49 2026-09-01 EDT
|
5-day change | 1st Jan Change | ||
| 13.30 SEK | -0.37% |
|
+0.76% | -32.83% |
Company Valuation: Annexin Pharmaceuticals AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 137.2 | 154.2 | 88.39 | 230.8 | 139.8 | 94.24 | - |
| Change | - | 12.35% | -42.68% | 161.1% | -39.44% | -32.58% | - |
| Enterprise Value (EV) | 137.2 | 154.2 | 66.97 | 214.4 | 139.8 | 94.24 | 94.24 |
| Change | - | 12.35% | -56.57% | 220.2% | -34.82% | -32.58% | 0% |
| P/E | - | - | - | - | - | - | - |
| PBR | - | - | - | - | - | - | - |
| PEG | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 2.04x | 2.85x |
| EV / Revenue | - | - | - | - | - | 2.04x | 2.85x |
| EV / EBITDA | - | -0x | - | -0x | -0x | -8.19x | -3.78x |
| EV / EBIT | - | -0x | -0x | -0x | -0x | -8.19x | -3.78x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | - | - | - | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | 46.3 | 33.1 |
| EBITDA 1 | - | -40.53 | - | -50.48 | -37.36 | -11.5 | -24.9 |
| EBIT 1 | - | -40.72 | -44.18 | -50.48 | -37.36 | -11.5 | -24.9 |
| Net income 1 | -52.14 | -40.73 | -44.05 | -50.25 | -36.89 | -11.5 | -24.9 |
| Net Debt | - | - | -21.42 | -16.34 | - | - | - |
| Reference price 2 | 100.00 | 99.80 | 26.00 | 43.30 | 19.80 | 13.35 | 13.35 |
| Nbr of stocks (in thousands) | 1,372 | 1,545 | 3,399 | 5,330 | 7,059 | 7,059 | - |
| Announcement Date | 2/3/22 | 2/7/23 | 2/9/24 | 2/6/25 | 2/5/26 | - | - |
1SEK in Million2
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 9.84M | |
| 20.25x | 7.09x | 14.33x | 1.44% | 68.13B | |
| 36.11x | 9.4x | 28.68x | 0.04% | 63.6B | |
| 29.63x | 6.32x | 16.43x | -.--% | 25.57B | |
| -74.57x | 14.38x | -69.34x | -.--% | 26.6B | |
| -15.53x | 5.87x | -7.38x | -.--% | 25.52B | |
| 52.62x | 19.47x | 39.5x | 0.29% | 18.23B | |
| 26.84x | 5.04x | 16.75x | -.--% | 19.69B | |
| 1309.77x | 37.93x | 827.81x | -.--% | 15.16B | |
| 16.88x | 5.01x | 11.7x | -.--% | 13.54B | |
| Average | 155.78x | 12.28x | 97.61x | 0.2% | 27.61B | |
| Weighted average by Cap. | 85.59x | 10.41x | 54.14x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ANNX Stock
- Valuation Annexin Pharmaceuticals AB
Select your edition
All financial news and data tailored to specific country editions
